Stopping Denosumab

Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis

(2018) Albrecht Werner Popp et al.   CALCIFIED TISSUE INTERNATIONAL

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Certainties and Uncertainties About Denosumab Discontinuation

(2018) Elena Tsourdi et al.   CALCIFIED TISSUE INTERNATIONAL

Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates

(2018) Liana Tripto-Shkolnik et al.   CALCIFIED TISSUE INTERNATIONAL

Effects and management of denosumab discontinuation

(2018) Roland Chapurlat   JOINT BONE SPINE

Underestimation of Vertebral Fractures After Denosumab Discontinuation

(2018) Olivier Lamy et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

(2017) Athanasios D Anastasilakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation

(2017) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years

(2017) A. Modi et al.   OSTEOPOROSIS INTERNATIONAL

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

(2017) M. B. Zanchetta et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Michael Gnant et al.   LANCET

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE